Protective effect of carnosine on white matter damage in corpus striatum induced by chronic cerebral hypoperfusion

@article{Ma2018ProtectiveEO,
  title={Protective effect of carnosine on white matter damage in corpus striatum induced by chronic cerebral hypoperfusion},
  author={Jing Ma and Haijing Yan and Ranran Wang and Shuhong Bo and Xiaotong Lu and Jian Zhang and Ajing Xu},
  journal={Neuroscience Letters},
  year={2018},
  volume={683},
  pages={54-60}
}
View on Elsevier
doi.org
7 Citations
Background Citations
1

7 Citations

Astaxanthin protects cognitive function of vascular dementia

Astaxanthin could improve cognitive impairment and hippocampal neurons in VD mice, which may be related to suppression of inflammatory response and oxidative stress.

A3 adenosine receptor agonist IB-MECA reverses chronic cerebral ischemia-induced inhibitory avoidance memory deficit.

Neuroprotective Potential of Carnosine in Cerebrovascular Diseases

This review is intended to provide a detailed overview of the neuroprotective role of carnosine in cerebrovascular diseases and summarize existing evidence from cell and animal studies.

Lipopolysaccharide exposure induces oxidative damage in Caenorhabditis elegans: protective effects of carnosine

Carnosine treatment protected against LPS injury by decreasing oxidative stress and inhibiting apoptosis through the p38 MAPK pathway and rescued behavioral phenotypes.

Protective Effects of Baicalin on Lipopolysaccharide-Induced Injury in Caenorhabditis elegans

Baicalin treatment protects against LPS-induced injury by decreasing oxidative stress, repressing the inflammatory cascade, and inhibiting apoptosis.

Comprehensive Evaluation of White Matter Damage and Neuron Death and Whole-Transcriptome Analysis of Rats With Chronic Cerebral Hypoperfusion

WMD and cortical neuronal death are worthy of attention in the pathogenesis of CCH, and potential evidence at the whole-transcription level for CCH is provided, offering candidate biomarkers and therapeutic targets.

Carnosine Prevents Aβ-Induced Oxidative Stress and Inflammation in Microglial Cells: A Key Role of TGF-β1

The data suggest a multimodal mechanism of action of carnosine underlying its protective effects on microglial cells against Aβ toxicity with a key role of TGF-β1 in mediating these protective effects.

References

SHOWING 1-10 OF 38 REFERENCES

Astroglial NF-kB contributes to white matter damage and cognitive impairment in a mouse model of vascular dementia

The results imply that pro-inflammatory changes in white matter astrocytes may represent an important detrimental component in the pathogenesis of vascular cognitive impairment, and that targeting these pathways may lead to novel therapeutic strategies.

Role of histidine/histamine in carnosine-induced neuroprotection during ischemic brain damage

Comorbid Rat Model of Ischemia and β‐Amyloid Toxicity: Striatal and Cortical Degeneration

The results suggest an insight into the relationship between cortical/striatal atrophy, pathology and functional impairment in the combined models of stroke and Abeta toxicity.

Effect of selective serotonin reuptake inhibitors on expression of 5-HT1AR and neurotransmitters in rats with vascular dementia.

Model animals demonstrated elongated escape latency, lower platform crossing times, and significant injuries to hippocampal CA1 neurons, suggesting that SSRIs may improve cognitive dysfunction of VD rats, possibly by stimulating expression of neurotransmitters and protecting neurons.

Blood and CSF biomarkers in brain subcortical ischemic vascular disease: Involved pathways and clinical applicability

  • A. Vilar-BerguaI. Riba-Llena J. Montaner
  • Biology, Medicine
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 2016
To translate these findings into clinical practice and use biomarkers to early diagnosis and monitoring vascular cognitive impairment would require the replication of candidate markers in large-scale, multicenter, and prospectively designed studies.

Selective Neuronal Loss in Ischemic Stroke and Cerebrovascular Disease

  • J. BaronH. YamauchiM. FujiokaM. Endres
  • Biology, Psychology
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 2014
Selective neuronal loss may also develop at sites remote from infarcts, representing secondary ‘exofocal’ phenomena akin to degeneration, potentially related to poststroke behavioral or mood impairments again amenable to therapy.

Mucosal Tolerization to E-Selectin Protects against Memory Dysfunction and White Matter Damage in a Vascular Cognitive Impairment Model

  • H. WakitaC. Ruetzler J. Hallenbeck
  • Biology, Psychology
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 2008
This model finds that repetitive intranasal administration of recombinant E-selectin to induce mucosal tolerance and to target immunomodulation to activating blood vessels potently suppresses both white matter (and possibly gray matter) damage and markers of vessel activation.

Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia.

YKL-40 differentiates between AD and controls and between stable mild cognitive impairment (MCI) and those progressing to AD and vascular dementia (VaD), and may be used as safety markers for monitoring CNS inflammation and microglia activation in clinical trials.

Recent Progress in Therapeutic Strategies for Ischemic Stroke

iPSCs have a potential to provide neural cells after ischemic brain injury if tumorigenesis is properly controlled and are transplanted into the ipsilateral striatum and cortex at 24 h after cerebral ischemia, suggesting that iPSCs could supply a great number of doublecortin-positive neuroblasts but also formed tridermal teratoma in the ischeic brain.

Rivastigmine for vascular cognitive impairment.

The efficacy of rivastigmine compared with placebo in the treatment of people with vascular cognitive impairment (VCI), vascular dementia or mixed dementia was assessed and no significant difference was found on any outcome measure relevant to cognition, neuropsychiatric symptoms, function or global rating.